Recent advances in the treatment of multiple myeloma have increased the need for accurate
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …

Minimal residual disease (MRD) assessment is incorporated in an increasing number of
multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a …

PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS)
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …

PURPOSE Assessing measurable residual disease (MRD) has become standard with many
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …

PURPOSE 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed
tomography (CT) is currently the standard technique to define minimal residual disease …

Patients with multiple myeloma (MM) carrying standard-or high-risk cytogenetic
abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis,
workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy …

Abstract Deciphering Multiple Myeloma evolution in the whole bone marrow is key to inform
curative strategies. Here, we perform spatial-longitudinal whole-exome sequencing …

The development of novel agents has transformed the treatment paradigm for multiple
myeloma, with minimal residual disease (MRD) negativity now achievable across the entire …